{"id":136294,"date":"2022-11-10T03:23:56","date_gmt":"2022-11-10T08:23:56","guid":{"rendered":"https:\/\/44.250.171.167\/?p=136294"},"modified":"2022-11-17T09:14:09","modified_gmt":"2022-11-17T14:14:09","slug":"dr-lal-pathlabs-ltd-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Dr Lal PathLabs Ltd Q2 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/lAaNZKEvjOc?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Dr Lal PathLabs Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/LALPATHLAB\/\">LALPATHLAB<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:16:43] Rahul Agarwal with Incred Capital enquired about 2Q23 performance according to the company\u2019s expectations. Arvind Lal EC said the company\u2019s opinion is that the performance is slightly in line with what it was doing earlier.<\/li>\n<\/ul>\n<ul>\n<li>[00:17:20] Rahul Agarwal of Incred Capital also asked that on Suburban, non-COVID revenue being flat QoQ. Arvind Lal EC replied that the company expected slightly higher growth, but there were some challenges in stabilizing the asset. However, going forward the company expects to bounce back on this.<\/li>\n<\/ul>\n<ul>\n<li>[00:17:39] Rahul Agarwal from Incred Capital enquired about staff cost declining from 1Q23 to 2Q23 to INR91 crores and if there is any one-offs. Ved Prakash Goel CFO clarified that there is a charge of RSU, which was reduced by about INR8.5 crores.<\/li>\n<\/ul>\n<ul>\n<li>[00:20:33] Sriraam Rathi of BNP Paribas enquired about margins going forward. Ved Prakash Goel CFO answered that 2Q is always higher margin quarter. LALPATHLAB said it will be able to maintain its margins going forward, which used to be pre-COVID level of around 26%, including Suburban.<\/li>\n<\/ul>\n<ul>\n<li>[00:22:06] Sriraam Rathi of BNP Paribas asked about revenue trajectory for 2H23, if it will be lower. Arvind Lal EC said that 3Q is the lower quarter in the company\u2019s portfolio, with 2Q being the highest.<\/li>\n<\/ul>\n<ul>\n<li>[00:32:22] Prakash Kapadia from Anived Portfolio asked about EBITDA margins going forward for Suburban from current levels. Arvind Lal EC said it\u2019s early stage. The focus right now is to stimulate topline growth than worry about EBITDA margins. The immediate focus is to be able to build collection infrastructure in Mumbai.<\/li>\n<\/ul>\n<ul>\n<li>[00:34:33] Prakash Kapadia of Anived Portfolio enquired that on the test menu if that\u2019s going to be an important addition to Suburban to drive growth. Arvind Lal EC replied that that\u2019s the plan and it will happen once the accreditations are done. LALPATHLAB is also looking at a close integration between suburban and LPL test menu, leveraging both.<\/li>\n<\/ul>\n<ul>\n<li>[00:36:43] Sayantan Maji of Credit Suisse asked about the regions that grew faster compared to the corporate average in 2Q23. Arvind Lal EC said that the company\u2019s core markets of UP, Punjab, Rest of North, and South all grew at a very fast pace.<\/li>\n<\/ul>\n<ul>\n<li>[00:43:55] Nitin Agarwal of DAM Capital asked about the good patient volume growth number that the company would be looking at. Om Prakash Manchanda MD said it\u2019s difficult to give that figure as the industry is in a state of flux. The whole excitement created by COVID is dying down. So the real trend can be seen in the next two quarters.<\/li>\n<\/ul>\n<ul>\n<li>[00:45:56] Sameer Baisiwala of Morgan Stanley enquired about company\u2019s distribution expansion and if it\u2019s on track. Bharath Uppiliappan CEO answered that it\u2019s on track and the company is seeing good response from Tier 2 plus cities and in South. Also the expansion plan continues both on collection center and lab network.<\/li>\n<\/ul>\n<ul>\n<li>[00:48:52] Rishabh Tiwari with Allegro Capital asked about non-COVID revenue growth of 6.6% in 2Q23, and how much is coming from volume and price. Arvind Lal EC said that there is no price erosion. Bundled test and super specialty contribution is moving up. Therefore, half will be volume and half revenue realization, but not price increase.<\/li>\n<\/ul>\n<ul>\n<li>[00:53:30] Rishi Modi from Marcellus asked about the company doubling its tech expenses in the past few years and in which areas it\u2019s investing. Arvind Lal EC answered that on the front end, all digital properties like website, app etc. On supply chain side, LALPATH is putting lot of digital assets to monitor the sample flow.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&amp;A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired about 2Q23 performance according to the company\u2019s expectations. Arvind Lal EC said the company\u2019s opinion is that the performance is slightly in line with what it was doing earlier. [00:17:20] Rahul Agarwal of Incred [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights #LALPATHLAB #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8665,10169,1115],"class_list":["post-136294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-diagnostics","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136294,"position":0},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129608,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":136294,"position":1},"title":"Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145982,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136294,"position":2},"title":"Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 12, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:17:48] Rahul Agarwal from InCred Capital asked if 13-14% revenue growth can be seen next year, given the supportive base, low employee attrition, and faster growth outside Delhi NCR. Om Prakash MD said FY '23 was\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127290,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":136294,"position":3},"title":"Dr Lal PathLabs Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 11, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=q_lILVipT-E Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY22 Earnings Concall Management Update: The company is enhancing access of its services by strengthening omni-channel approach in cities and pursuing hub lab infrastructure in Tier 2 and Tier 3 towns. During 3Q22, the company successfully integrated AI in prostate\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":132298,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136294,"position":4},"title":"Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 3, 2022","format":false,"excerpt":"https:\/\/youtu.be\/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly non-COVID revenue of INR482 crore, a growth of 25% YoYs. Additionally, COVID revenue significantly declined by 91% from INR221 crore to INR21 crore in 1Q23. Q&A Highlights: Pooja\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":132319,"url":"https:\/\/alphastreet.com\/india\/earnings-infographic-dr-lal-pathlabs-q1-2023-revenue-and-profit-decline\/","url_meta":{"origin":136294,"position":5},"title":"Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline","author":"Manoj_Nair","date":"August 3, 2022","format":false,"excerpt":"Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for the first quarter of 2023. The company also announced an interim dividend of \u20b96 per share. First-quarter revenues dropped 17% year-over-year to \u20b9502.7 crores, hurt by a sharp\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=136294"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136294\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=136294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=136294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=136294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}